Home  /  Resource Library  /  CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Results of a phase Ib trial investigating CD47 immune checkpoint inhibitor Hu5F9-G4 combined with rituximab for B-cell lymphoma.